Treatment of Osteoporosis

Simonelli C, Weiss TW, Morancey J, Swanson L, Chen YT. Prevalence of vitamin D inadequacy in a minimal trauma fracture population. Curr Med Res Opin 2005;21:1069-74.10.1185/030079905X5059816004675Search in Google Scholar

Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen lossmediation by interleukin-6. Science 1992;257:88-91.10.1126/science.16211001621100Search in Google Scholar

Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, Garcia I. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 1997;99:1699-703.10.1172/JCI1193335079909120014Search in Google Scholar

Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 1991;88:6613-7.10.1073/pnas.88.15.6613521371907373Search in Google Scholar

Pennisi E. Drugs' link to genes reveals estrogen's many sides. Science 1996;273:1171.10.1126/science.273.5279.11718787121Search in Google Scholar

Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP. Human estrogen receptor transcriptional capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994;8:21-30.Search in Google Scholar

Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New Engl J Med 2003;349: 523-34.10.1056/NEJMoa03080812904517Search in Google Scholar

Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK. Effect of the women's health initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 2006;21:765-71.10.1359/jbmr.06011916734392Search in Google Scholar

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.10.1001/jama.280.7.6059718051Search in Google Scholar

Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.10.1001/jama.288.7.87212186605Search in Google Scholar

Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG. Effects of estrogen plus progestin on health-related quality of life. New Engl J Med 2003;348:1839-54.10.1056/NEJMoa03031112642637Search in Google Scholar

Black LJ, Sato M, Rowley ER. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9.10.1172/JCI1169852937308282823Search in Google Scholar

Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Engl J Med 1997;337:1641-7.10.1056/NEJM1997120433723019385122Search in Google Scholar

Sambrook P. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)? Best Pract Res Clin Rheumatol 2005;19:975-81.10.1016/j.berh.2005.06.00716301191Search in Google Scholar

Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol raloxifene. Science 1996;273:1222-5.10.1126/science.273.5279.12228703055Search in Google Scholar

Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354-7.10.1126/science.270.5240.13547481822Search in Google Scholar

Barrett-Connor E, Mosca L, Collins P i sur. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. New Engl J Med 2006;355:125-37.10.1056/NEJMoa06246216837676Search in Google Scholar

Bevers TB. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother 2006;7:2301-7.10.1517/14656566.7.16.230117059385Search in Google Scholar

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud Ke, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;281:2189-97.10.1001/jama.281.23.218910376571Search in Google Scholar

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators. (CORE Investigators): Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61.10.1093/jnci/djh31915572757Search in Google Scholar

Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New Engl J Med 1990;322:1265-71.10.1056/NEJM1990050332218032109197Search in Google Scholar

Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-40.10.1124/mol.56.1.13110385693Search in Google Scholar

Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vananen HK, Hassinen IE. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol 2002;61:1255-62.Search in Google Scholar

Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-41.10.1006/abbi.1999.150210620343Search in Google Scholar

Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9.10.1359/jbmr.1998.13.4.5819556058Search in Google Scholar

van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999;255:491-4.10.1006/bbrc.1999.022410049736Search in Google Scholar

Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med 2002;2:571-7.10.2174/156652402336210412243249Search in Google Scholar

Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9(Suppl 2):S66-80.10.1007/PL00004164Search in Google Scholar

Iwamoto J, Takeda T, Sato Y. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin 2006;22:919-28.10.1185/030079906X10027616709313Search in Google Scholar

Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61.10.4065/80.7.85616007889Search in Google Scholar

Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. New Engl J Med 2004;350:1189-99.10.1056/NEJMoa03089715028823Search in Google Scholar

Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group. New Engl J Med 1998;338:485-92.10.1056/NEJM1998021933808019443925Search in Google Scholar

Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004;255:503-11.10.1111/j.1365-2796.2004.01317.xSearch in Google Scholar

Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;16:753-61.10.7326/0003-4819-144-10-200605160-00009Search in Google Scholar

de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW. STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. New Engl J Med 2006;355:675-84.10.1056/NEJMoa053569Search in Google Scholar

Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results form a multinational, double-blind, placebocontrolled trial. J Clin Endocrinol Metab 2000;85:1895-900.Search in Google Scholar

Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11.10.1007/s00223-002-2011-8Search in Google Scholar

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52.10.1001/jama.282.14.1344Search in Google Scholar

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.10.1007/s001980050010Search in Google Scholar

Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-ranging study. Bone 1996;19:527-33.10.1016/S8756-3282(96)00229-3Search in Google Scholar

Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001;16:1871-8.10.1359/jbmr.2001.16.10.1871Search in Google Scholar

Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schoter KH. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298-307.10.1016/S0002-9343(97)00249-0Search in Google Scholar

Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-22.10.1359/JBMR.05031316007327Search in Google Scholar

Silverman SL. Calcitonin. Endocrinol Metab Clin North Am 2003;32:273-84.10.1016/S0889-8529(02)00060-9Search in Google Scholar

Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 1983;57:819-24.10.1210/jcem-57-4-819Search in Google Scholar

Mehta NM, Malootian A, Gilligan JP. Calcitonin for osteoporosis and bone pain. Curr Pharm Des 2003;9:2659-76.10.2174/1381612033453622Search in Google Scholar

Ofluoglu D, Akyuz G, Unay O, Kayhan O. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol 2007;26:44-9.10.1007/s10067-006-0228-zSearch in Google Scholar

Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76.Search in Google Scholar

Lyritis GP, Trovas G. Analgesic effects of calcitonin. Bone 2002;30:71-4.10.1016/S8756-3282(02)00714-7Search in Google Scholar

Miyauchi A, Notoya K, Taketomi S. Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function. Endocrinology 1996;137:3544-50.10.1210/endo.137.8.8754785Search in Google Scholar

Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, Gennari C, Reginster JY; Ipriflavone Multicenter European Fracture Study. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001;285:1482-8.10.1001/jama.285.11.1482Search in Google Scholar

Darby AJ, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calcif Tissue Int 1981;33:199-204.10.1007/BF02409438Search in Google Scholar

Parsons JA, Potts JT Jr. Physiology and chemistry of parathyroid hormone. Clin Endocrino Metab 1972;1:33-78.10.1016/S0300-595X(72)80050-1Search in Google Scholar

Canalis E, Centrella M, Burch W, McCarthy TL. Insulinlike growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 1989;8:60-5.10.1172/JCI1138853036432910920Search in Google Scholar

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-41.10.1056/NEJM200105103441904Search in Google Scholar

Hirano T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999;14:536-45.10.1359/jbmr.1999.14.4.536Search in Google Scholar

Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53.10.1359/jbmr.2001.16.10.1846Search in Google Scholar

Lau KH, Farley JR, Freeman TK, Baylink DJ. A proposed mechanism of the mitogenic action of fluoride on bone cells: inhibition of the activity of an osteoblastic acid phosphatase. Metabolism 1989;38:858-68.10.1016/0026-0495(89)90232-1Search in Google Scholar

Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. New Engl J Med 2003;349:1216-26.10.1056/NEJMoa03572514500805Search in Google Scholar

Ettinger B, San Martin JA, Crans GG, Pavo I 2004 Differential effects of teriparatide after treatment with raloxifene or alendronate. J Bone Miner Res19:745-51.10.1359/jbmr.040117Search in Google Scholar

Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998;13:1051-5.10.1359/jbmr.1998.13.6.10519626638Search in Google Scholar

Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003;349:1207-15.10.1056/NEJMoa03197514500804Search in Google Scholar

Whitfield JF. The bone growth-stimulating PTH and osteosarcoma. Medscape Womens Health 2001;6:7.Search in Google Scholar

Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science 1983;222:330-2.10.1126/science.66230796623079Search in Google Scholar

Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ 3rd. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. New Engl J Med 1990;322:802-9.10.1056/NEJM1990032232212032407957Search in Google Scholar

Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, Parfitt AM. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1991;1:155-61.10.1007/BF016254461790403Search in Google Scholar

Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl J Med. 2004;350:459-68.10.1056/NEJMoa02243614749454Search in Google Scholar

Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, Allain P, Tsouderos Y, Meunier PJ. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 1996;11:1302-11.10.1002/jbmr.56501109158864905Search in Google Scholar

Marie PJ, Amman P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121-29.10.1007/s00223001005511683526Search in Google Scholar

Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 2002;51:906-11.10.1053/meta.2002.3336012077740Search in Google Scholar

Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, Tsouderos Y. An uncoupling agent containin strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;9:607-15.Search in Google Scholar

Boivin G, Meunier PJ. The mineralization of bone tissue: a forgotten dimension in osteoporosis research. Osteoporosis Int 2003;14(Suppl 3):S19-24.10.1007/s00198-002-1347-212730799Search in Google Scholar

Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22.10.1210/jc.2004-177415728210Search in Google Scholar

Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:206-6.Search in Google Scholar

Quarles LD. Cation sensing receptors in bone: A novel paradigm for regulation bone remodeling? J Bone Miner Res 1997;12:1971-4.10.1359/jbmr.1997.12.12.19719421229Search in Google Scholar

Baron R. Biology of the osteoclast. U: Mundy GR, Martin TJ, urednici. Physiology and Pharmacology of Bone. Handbook of Experimental Pharmacology; Berlin: Springer-Verlag; 1993. str. 111-47.10.1007/978-3-642-77991-6_3Search in Google Scholar

Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990;345:442-4.10.1038/345442a02188141Search in Google Scholar

Felix R, Cecchini MG, Hofstetter W, Elford PR, Stutzer A, Fleisch H. Impairment of macrophage colonystimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J Bone Miner Res 1990;5:781-9.10.1002/jbmr.5650050716Search in Google Scholar

Kodama H, Yamasaki A, Nose M, Niida S, Ohgame Y, Abe M, Kumegawa M, Suda T. Congenital osteoclast deficiency in osteopetrotic op/op mice is cured by injections of macrophage colony stimulating factor. J Exp Med 1991;173:269-72.10.1084/jem.173.1.269Search in Google Scholar

Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64:693-702.10.1016/0092-8674(91)90499-OSearch in Google Scholar

Yoneda T, Lowe C, Lee CH, Gutierrez G, Niewolna M, Williams PJ, Izbicka E, Uehara Y, Mundy GR. Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo.J Clin Invest 1993;91:2791-5.10.1172/JCI1165214433468514886Search in Google Scholar

Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M. Inhibition of osteoclastic bone resorption in vivo by echistatin an "arginylglycyl-aspartyl" (RDG) containing peptide. Endocrinology 1993;132:1411-3.10.1210/endo.132.3.84401958440195Search in Google Scholar

Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG, Teitelbaum SL. A peptidomimetic antagonist of the α_v β₃ integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.J Clin Invest 1997;99:2284-92.10.1172/JCI1194045080619151803Search in Google Scholar

Horton MA, Davies J. Perspectives-adhesion receptors in bone. J. Bone Miner Res 1989;4:803-8.10.1002/jbmr.56500406032481941Search in Google Scholar

Vaes E. The action of parathyroid hormone on the excretion and synthesis of lysosomal enzymes and on the extracellular release of acid by bone cells. J Cell Biol 1968;39:676-97.10.1083/jcb.39.3.67621075415699937Search in Google Scholar

Eilon G, Raisz LG. Comparison of the effects of stimulators and inhibitors of resorption on the release of lysosomal enzymes and radioactive calcium from fetal bone in organ culture. Endocrinology 1978;103:1969-75.10.1210/endo-103-6-1969748028Search in Google Scholar

Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, Levy MA. Proteolytic activity of human osteoclast cathepsin K-expression, purification, activation, and substrate identification. J Biol Chem 1996;271:12517-24.10.1074/jbc.271.21.125178647860Search in Google Scholar

Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M. Cathepsin K, but not cathepsin B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996;271:12511-6.10.1074/jbc.271.21.12511Search in Google Scholar

Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000;192:463-74.10.1084/jem.192.4.463Search in Google Scholar

Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of soluble RANK-IgG Fc (RANK.Fc) fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001;61:2572-8.Search in Google Scholar

Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992;90:1622-7.10.1172/JCI116032Search in Google Scholar

Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 1993;90:4485-9.10.1073/pnas.90.10.4485Search in Google Scholar

Abu-Amer Y, Tondravi MM. NFkappaB and bone: the breaking point. Nat Med 1997;3:1189-90.10.1038/nm1197-1189Search in Google Scholar

Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003;111:1771-82.10.1172/JCI16198Search in Google Scholar

Tremollieres FA, Pouilles JM, Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 1993;77:683-6.Search in Google Scholar

Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207.10.1016/S0092-8674(00)81558-5Search in Google Scholar

Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass indeks on bone mineral density in men and women: the Framingham Study. J Bone Miner Res 1993;8:567-73.10.1002/jbmr.56500805078511983Search in Google Scholar

Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005;11:76-81.10.1016/j.molmed.2004.12.00415694870Search in Google Scholar